On April 1, innovative drug stocks led the Hong Kong market with strong gains. The Huabao Hong Kong Stock Connect Innovative Drug ETF (520880), which focuses exclusively on innovative drug R&D companies, demonstrated aggressive momentum in the rebound, surging towards a 6% increase on heavy volume. Trading volume exceeded 640 million yuan in less than half a day, significantly surpassing the previous day's full-day total. The healthcare sector in Hong Kong also showed strength, with the Huabao Hong Kong Stock Connect Healthcare ETF (159137) rising over 4%.
Focusing on the Hong Kong Stock Connect innovative drug sector, Lepu Biopharma (06978) led the gains, rising over 15%. Companies like RemeGen, Haisco Pharmaceutical, LEXEO Therapeutics, Boan Biotechnology, and Ascentage Pharma all saw increases exceeding 10%. Leading weighted constituents, including Akeso, Innovent Biologics, and Sino Biopharmaceutical, rose over 6%. BeiGene advanced more than 7%, while 3SBio increased over 9%.
According to statistics, 47 constituent companies of the Huabao Hong Kong Stock Connect Innovative Drug ETF (520880) have released their 2025 annual reports. Among them, 28 companies reported profits, with 25 achieving double-digit year-over-year net profit growth. Ten companies saw net profit growth rates exceed 100%, with HUTCHMED reporting an increase of over 11 times and Innovent Biologics growing over 9 times.
Regarding event catalysts, the American Association for Cancer Research (AACR) Annual Meeting is scheduled for April 17-22, 2026, in San Diego, USA. Reports indicate that over 100 Chinese pharmaceutical companies will present at AACR this year, showcasing nearly 400 research成果 covering multiple popular targets and前沿 technologies such as radiopharmaceuticals, DACs, cell therapy, and mRNA.
Analysis suggests that the Hong Kong healthcare sector, driven by policy support, successful international expansion, and relatively clean positioning, has the potential to demonstrate significant valuation elasticity and upward momentum.
To efficiently participate in the Hong Kong healthcare sector rebound, consider these two T+0 instruments: For innovative drugs, the Huabao Hong Kong Stock Connect Innovative Drug ETF (520880) provides 100% exposure to innovative drug R&D companies. Its top ten holdings account for over 70% of the portfolio, highlighting its focus on industry leaders. For broader healthcare exposure, the Huabao Hong Kong Stock Connect Healthcare ETF (159137) allocates approximately 70% of its portfolio to CXO and AI healthcare, while also covering innovative drugs and medical devices (including brain-computer interfaces). Its top ten holdings include稀缺 internet healthcare leaders like JD Health and AliHealth.
Data Source: China Securities Index Company, Shanghai, Shenzhen, and Hong Kong Stock Exchanges, etc. Note: The ETF does not charge a sales service fee. When investors subscribe for or redeem fund shares, the subscription/redemption agent may charge a commission of up to 0.5%, which includes relevant fees charged by the stock exchange and registration机构. Detailed fund fee structures are available in the respective fund legal documents.
Risk Warning: The index constituents mentioned are for illustrative purposes only. Descriptions of individual stocks are not intended as investment advice of any form and do not represent the holdings or trading动向 of any fund managed by the management人. The fund manager assesses the risk rating of the Hong Kong Stock Connect Innovative Drug ETF and the Hong Kong Stock Connect Healthcare ETF as R4 - Medium-High Risk, suitable for Aggressive (C4) and above investors. Any information appearing in this article (including but not limited to individual stocks, commentary, forecasts, charts, indicators, theories, and any form of expression) is for reference only. Investors are responsible for any independent investment decisions. Furthermore, any views, analysis, or forecasts herein do not constitute investment advice of any kind to the reader, and no responsibility is accepted for any direct or indirect losses resulting from the use of this content. The performance of other funds managed by the fund manager does not guarantee the performance of this fund. Past performance of a fund is not indicative of its future results. Fund investment carries risks.
The MACD golden cross signal has formed, and these stocks are performing well.
Comments